Navigation Links
ExcaliburPlus PC Electrosurgery Generator, 240V, 50Hz

ProductsExcaliburPlus PC Electrosurgery Generator, 240V, 50Hz
Company CONMED Corporation
Item ExcaliburPlus PC Electrosurgery Generator, 240V, 50Hz
Features It is the only ESU that allows the surgeon to adjust power settings from the surgical field with a standard ES pencil. Excalibur Plus PC patented controlled output voltage in cut maintains minimum necessary voltage for smooth cutting through various impedance tissues with minimal thermal damage. Pure and three blend cuts, "Pin Point" coagulation with minimal arcing and deep thermal necrosis, wide pattern fulguration, 10000 Volts peak to peak in spray coagulation.
Description The ExcaliburPlus PC is the most powerful isolated ESU with 10,000 V PTP in spray coag.
Info CONMED Corporation
Customer Service: (315) 797-8375
Web site: http://www.conmed.com/

Related medicine products :

1. ExcaliburPlus PC
2. ExcaliburPlus PC, 110V, 60Hz
3. ExcaliburPlus PC, 220V, 50Hz
4. ExcaliburPlus PC, 240V, 50Hz
5. ExcaliburPlus PC, 100V, 50Hz/60Hz
6. ExcaliburPlus PC Electrosurgery Generator, 110V, 60Hz
7. ExcaliburPlus PC Electrosurgery Generator, 220V, 50Hz
8. ExcaliburPlus PC Electrosurgery Generator, 100V, 50Hz/60Hz
9. Sabre 2400 Electrosurgery Generator, 110V, 60Hz
10. Sabre 2400 Electrosurgery Generator, 100V, 50Hz/60Hz
11. Sabre 2400 Electrosurgery Generator, 220V, 50Hz
Straight, single action bone forceps to excise, trim and sculpt bone.
Diamond Point Bone Probe with Ortho-Grip® silicone rubber palm style handles and,stainless steel impactor caps.
CapSureSP Novus 5594 is a J-shaped, endocardial, tined pacing lead. provide the stable, low pacing thresholds and large sensing potentials already proven with CapSure SP steroid-eluting leads but wi
The Guidant Fineline II Sterox Atrial J is a steroid-eluting pacing lead designed for permanent implantation for either atrial or ventricular applications.
Medicine Products:
(Date:12/3/2008)...RANCISCO, Dec. 3 The Am...rgest professional association of blood specialist...ASH Annual Meeting from December 6-9, 2008, at the...will showcase the latest research and treatments f...en anniversary, there will also be several special...
(Date:12/3/2008)... ECPI College of Technology ha...uth Carolina veterans who have served in Iraq or A... introduced in fall 2005 and is also available to ...ve served in these regions. Up to $150,000 in scho...es at ECPI College of Technology or Medical Career...
(Date:12/3/2008)...ecember 3, 2008 (BRONX, NY) A new study led by r...of Yeshiva University has clarified how two major ...eurologic complications. The finding, published i...et for drugs that could prevent HIV-associated dem...cation in people with AIDS. Even with anti-retrovi...
(Date:12/3/2008)...nts who had aggressive surgeries were free of tumo...s , , ROCHESTER, Minn., Dec. 3 /PRNewswire... patients with low-grade gliomas survived longest ...sfully remove the entire tumor. If safely removing...ved significantly longer when surgery was followed...
Breaking Medicine News(10 mins):Health News:50th Annual Meeting of the American Society of Hematology Will Feature Breakthrough Research in Blood Diseases 2Health News:50th Annual Meeting of the American Society of Hematology Will Feature Breakthrough Research in Blood Diseases 3Health News:50th Annual Meeting of the American Society of Hematology Will Feature Breakthrough Research in Blood Diseases 4Health News: ECPI College of Technology and Medical Careers Institute Announce Extension for South Carolina Military Scholarship Opportunity 2Health News:Study sheds light on causes of HIV dementia 2Health News:Study sheds light on causes of HIV dementia 3Health News:Mayo Clinic Identifies Best Treatments for Long-Term Survival in Brain Tumor Patients 2Health News:Mayo Clinic Identifies Best Treatments for Long-Term Survival in Brain Tumor Patients 3
... in Scotland are calling for an increase in the ag...es. This is the latest attempt to deter young peop... was made at the opening of the annual conference ... the occasion said that the current law of 16 year...
... is seen as a landmark achievement, scientists at ...ve developed a new drug to control// and cure depr...the country. "The new drug has been found to be s... drugs. It is also free of side effects," a senior...
... therapies, including cognitive rehabilitation, co...ation, psychotherapy, and behavioral training// co...e symptoms of schizophrenia. An issue of the Harv... symptoms have more effect on the quality of life ...
...vantage Indian pharma companies and the needy pati...ase life-saving drugs, with global pharma giants l...s commanding multi-billion annual sales. Domesti...s Laboratories are being touted as major beneficia...
Other Medicine News:
(Date:12/2/2008)...east-specific gamma imaging,(BSGI) is effective i... or by,clinical exam, according to a study presen...al Society of North America (RSNA). , "BSGI...cancer-invasive,lobular carcinoma," said lead aut...and director of the Breast Imaging and Interventio...
(Date:12/2/2008)...-- Micromet, Inc. (Nasdaq: MITI ), a biopharmace...odies for the treatment of cancer, inflammation an... entered into an agreement expanding its Committed... Capital Limited, a private investment group. Und...mitted to provide up to $75 million of capital dur...
(Date:12/1/2008)...td today announced the initiation of a Phase 1/2 c...e JAK2 inhibitor, in leading medical centers in Au...fibrosis (CIMF). , , The trial is designed... in patients with CIMF and is expected to enrol up...ll assess the safety profile and evaluate the phar...
(Date:12/1/2008)...stCall/ -- Genaera Corporation (Nasdaq: GENR ) ...in study MSI-1436C-102 (Study 102), the multiple a...-1436) in overweight and obese type 2 diabetics. M...f type 2 diabetes and obesity which works centrall...pathways through the highly selective inhibition o...
Breaking Medicine Technology:New Breast Imaging Technology Targets Hard-to-Detect Cancers 2New Breast Imaging Technology Targets Hard-to-Detect Cancers 3Micromet Expands Committed Equity Financing Facility to $75 Million 2Micromet Expands Committed Equity Financing Facility to $75 Million 3Micromet Expands Committed Equity Financing Facility to $75 Million 4Micromet Expands Committed Equity Financing Facility to $75 Million 5Micromet Expands Committed Equity Financing Facility to $75 Million 6S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis 2S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis 3Genaera Begins Phase 1b Trial of Trodusquemine (MSI-1436) in Overweight and Obese Type 2 Diabetics 2Genaera Begins Phase 1b Trial of Trodusquemine (MSI-1436) in Overweight and Obese Type 2 Diabetics 3Completely novel action of insulin unveiled 28847 1Completely novel action of insulin unveiled 28847 2Big Lottery to fund scientific research 28845 1Very cold ice films in laboratory reveal mysteries of universe 5734 1Very cold ice films in laboratory reveal mysteries of universe 5734 2Very cold ice films in laboratory reveal mysteries of universe 5734 312 outstanding young scientists named as EMBO Young Investigators 5732 112 outstanding young scientists named as EMBO Young Investigators 5732 2
...amp; MADISON, N.J.--(BUSINESS WIRE)--Jun 28, 2007,...nd Wyeth,Pharmaceuticals, a division of Wyeth (NYS...hree-month open-label extension study of,subcutane...nduced,constipation (OIC) in patients with advance...ed at the Multinational Association of,Supportive ...
...-(BUSINESS WIRE)--Jun 28, 2007 - CombinatoRx,Inco...y results of,its randomized, blinded, placebo-cont...rheumatoid arthritis (RA). The trial,compared CRx-...DMARD) to placebo plus DMARD (control) in subjects...is trial, CRx-150 demonstrated,statistically signi...
Other Medicine Technology:Progenics and Wyeth Announce Positive Results from Three-Month,Clinical-Extension Study of Subcutaneous Methylnaltrexone for the,Treatment of Opioid-Induced Constipation in Patients with Advanced,Illness 2Progenics and Wyeth Announce Positive Results from Three-Month,Clinical-Extension Study of Subcutaneous Methylnaltrexone for the,Treatment of Opioid-Induced Constipation in Patients with Advanced,Illness 3Progenics and Wyeth Announce Positive Results from Three-Month,Clinical-Extension Study of Subcutaneous Methylnaltrexone for the,Treatment of Opioid-Induced Constipation in Patients with Advanced,Illness 4Progenics and Wyeth Announce Positive Results from Three-Month,Clinical-Extension Study of Subcutaneous Methylnaltrexone for the,Treatment of Opioid-Induced Constipation in Patients with Advanced,Illness 5Progenics and Wyeth Announce Positive Results from Three-Month,Clinical-Extension Study of Subcutaneous Methylnaltrexone for the,Treatment of Opioid-Induced Constipation in Patients with Advanced,Illness 6CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and,Pain, but Not CRP 2CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and,Pain, but Not CRP 3CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and,Pain, but Not CRP 4CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and,Pain, but Not CRP 5